Press Releases

PTC is committed to serving the interests of all our stakeholders.
Pam & Kelsey
Living with PKU, United States

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Feb 27, 2015
PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update
-Translarna™ approved in the European Union and recently launched in Germany-
-42 patients now on commercial Translarna therapy-
-Rolling NDA submitted for Translarna in the US-
-Confirmatory Phase 3 ACT CF trial initiated-
-SMA program advanced into Phase 2 MOONFISH study-
-Advanced internally developed programs to enhance the pipeline-
-Maintained strong balance sheet with $315 million in cash-
Read More
Feb 16, 2015
PTC Therapeutics to Participate at Upcoming March Investor Conferences
SOUTH PLAINFIELD, N.J. , Feb. 16, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen and Company 35th Annual Health Care Conference at The Boston Marriott Copley Place in Boston, MA on Monday,
Read More
Feb 05, 2015
PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , Feb 5, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: 2015 Leerink Global Healthcare Conference at the Waldorf Astoria in New York on Thursday, February 12 th RBC 2015
Read More